coadministered cagrilintide and semaglutide in adults with overweight or obesity Coadministered Cagrilintide and Semaglutide in Adults Updates in Medicine | CagriSema

Nausea affects up to 25% of semaglutide users in early treatment phases

Losing weight can be a challenging journey, but with the right guidance and support, achieving your goals becomes much more attainable

Understanding the current evidence helps patients make informed decisions about semaglutide therapy with PlexusDx

Each patch is made with a comfortable, skin-friendly adhesive that helps it stay securely in place during regular daily activities

Non-GLP-1 obesity drugs are emerging, with this landscape expected to surge 50-fold over the next five years, generating $15.5bn in 2031.

Analysis of supportive secondary endpoints: Semaglutide 2.4 mg was also associated with improvements in multiple cardiovascular risk factors, including waist circumference, glycated haemoglobin level, systolic and diastolic blood pressure, high-sensitivity C-reactive protein and lipids